GLUCOCORTICOIDS, INTERFERON AND FC RECEPTORS
糖皮质激素、干扰素和 FC 受体
基本信息
- 批准号:3231477
- 负责人:
- 金额:$ 21.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-12-01 至 1994-11-30
- 项目状态:已结题
- 来源:
- 关键词:Streptococcus antibody receptor antigen presentation cell mediated cytotoxicity cytokine flow cytometry glucocorticoids hormone regulation /control mechanism human subject immunoglobulin G interferons leukocyte activation /transformation macrophage monocyte nucleic acid probes phagocytosis pharyngitis receptor expression tissue /cell culture
项目摘要
DESCRIPTION (Adapted from applicant's abstract): Glucocorticoids, which
are widely used to suppress immune function, are key agents for treatment
of autoimmune disorders in which Fc receptors for IgG (Fc gamma R) appear
to play a major role. However, the mechanisms by which glucocorticoids
alter Fc gamma R functions remain unclear. Since the development of
monoclonal antibodies (mAbs) that discriminate each of three major Fc gamma
R types (Fc gamma RI, II and III), the specific effects of glucocorticoids,
alone and in concert with immune cytokines, can now be definitively
investigated. Moreover, cDNAs and additional mAbs have recently been
developed that discriminate not only the major Fc gamma R types, but also
subtypes that probably represent gene duplications, alternate processing
and allotypic differences. Furthermore, approaches utilizing these mAbs
have been developed that permit measurement of the number and functional
activity of most of these Fc gamma R types and subtypes. Using this base
of reagents and approaches, many developed by the investigator, he proposes
to elucidate the effects of glucocorticoids, gamma interferon (IFN-gamma),
and selected other immune cytokines on the expression and function of each
Fc gamma R type and subtype. These studies will include quantitative flow
cytometry to measure the number of each Fc gamma R expressed on monocytes,
macrophages and PMN's that are cultured with glucocorticoids and/or
recombinant immune cytokines. cDNA probes will be used to determine
hormonal effects on expression of mRNA specific to each Fc gamma R.
Functional assays will include glucocorticoid effects on antibody-dependent
cellular cytotoxicity (ADCC), phagocytosis, and antigen processing and
presentation mediated via each Fc gamma R type and subtype. Since other
molecules certainly influence phagocyte functions, the applicant will
characterize two IFN-gamma and glucocorticoid-inducible surface molecules
of monocytes that we will have identified using new mAbs. Finally, to
relate the in vitro findings on the role of glucocorticoids in regulation
of Fc receptor expression and function to in vivo myeloid cell activation,
the applicant would examine phagocytes from patients with streptococcal
pharyngitis. Using this as a natural in vivo model system for leukocyte
activation, he would determine whether there are similar glucocorticoid
effects on phagocytes activated in vivo and those activated in cell culture
by immune cytokines. The applicant states that these studies would provide
a basis for understanding the interrelationships among myeloid cell Fc
gamma R and the hormonal influences that regulate the functional activities
of phagocytes.
描述(改编自申请人摘要):糖皮质激素,
广泛用于抑制免疫功能,是治疗的关键药物,
IgG的Fc受体(Fc γ R)出现的自身免疫性疾病
发挥重要作用。 然而,糖皮质激素
改变Fc γ R功能仍不清楚。 发展至今
区分三种主要Fc γ
R型(Fc γ RI、II和III),糖皮质激素的特异性作用,
单独和与免疫细胞因子一起,现在可以明确地
研究了 此外,cDNA和额外的mAb最近已经被用于治疗癌症。
开发了不仅区分主要Fc γ R类型,
可能代表基因复制的亚型,交替处理
和同种异型差异。 此外,利用这些mAb的方法
已经开发了允许测量的数量和功能
这些Fc γ R类型和亚型中的大多数的活性。 利用这个基地
他提出,许多试剂和方法是由研究人员开发的,
为了阐明糖皮质激素、γ干扰素(IFN-γ)的作用,
并选择其他免疫细胞因子对每种细胞因子的表达和功能进行研究。
Fc γ R类型和亚型。 这些研究将包括定量流动
流式细胞术以测量单核细胞上表达的每种Fc γ R的数量,
巨噬细胞和PMN与糖皮质激素和/或
重组免疫细胞因子。 cDNA探针将用于确定
激素对每种Fc γ R特异性mRNA表达的影响。
功能测定将包括糖皮质激素对抗体依赖性
细胞毒性(ADCC)、吞噬作用和抗原加工,
通过每种Fc γ R类型和亚型介导的呈递。 因为其他
分子肯定会影响吞噬细胞的功能,申请人将
表征两种IFN-γ和糖皮质激素诱导的表面分子
我们将用新的单克隆抗体鉴定单核细胞。 最后为
将糖皮质激素在调节中的作用的体外发现与
Fc受体表达和功能对体内髓样细胞活化的影响,
申请人将检查链球菌患者的吞噬细胞
咽炎。 使用此作为白细胞的天然体内模型系统
激活,他会确定是否有类似的糖皮质激素
对体内激活的吞噬细胞和细胞培养物中激活的吞噬细胞的影响
通过免疫细胞因子。 申请人表示,这些研究将提供
理解髓样细胞Fc之间相互关系的基础
γ R和调节功能活动的激素影响
吞噬细胞
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL GUYRE其他文献
PAUL GUYRE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL GUYRE', 18)}}的其他基金
SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES
SBIR 主题 081:针对传染性或免疫介导疾病的疫苗的佐剂开发
- 批准号:
10281989 - 财政年份:2020
- 资助金额:
$ 21.19万 - 项目类别:
Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM)
糖尿病前期和早期 2 型糖尿病 (T2DM) 中 IAPP 功能障碍的生物标志物
- 批准号:
10079720 - 财政年份:2020
- 资助金额:
$ 21.19万 - 项目类别:
DISCOVERY OF PARASITE-DERIVED TOLEROGENIC ADJUVANTS
寄生虫源致耐受佐剂的发现
- 批准号:
10017567 - 财政年份:2019
- 资助金额:
$ 21.19万 - 项目类别:
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
开发苏丹病毒单克隆抗体疗法 CM-SV1
- 批准号:
10132229 - 财政年份:2018
- 资助金额:
$ 21.19万 - 项目类别:
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
开发苏丹病毒单克隆抗体疗法 CM-SV1
- 批准号:
10075623 - 财政年份:2018
- 资助金额:
$ 21.19万 - 项目类别:
Development of GIFT4: a B cell focused immunotherapy for cancer
GIFT4 的开发:针对癌症的 B 细胞免疫疗法
- 批准号:
9345070 - 财政年份:2017
- 资助金额:
$ 21.19万 - 项目类别:
Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL
CTCL 的下一代免疫毒素疗法 BILT 的临床前开发
- 批准号:
8831907 - 财政年份:2015
- 资助金额:
$ 21.19万 - 项目类别:
Physiological vs. pharmacological effects of glucocorticoids on human monocytes.
糖皮质激素对人单核细胞的生理与药理作用。
- 批准号:
8114343 - 财政年份:2011
- 资助金额:
$ 21.19万 - 项目类别:
Physiological vs. pharmacological effects of glucocorticoids on human monocytes.
糖皮质激素对人单核细胞的生理与药理作用。
- 批准号:
8227989 - 财政年份:2011
- 资助金额:
$ 21.19万 - 项目类别:
Glucocorticoid/cytokine mechanisms in endotoxemia.
内毒素血症中的糖皮质激素/细胞因子机制。
- 批准号:
6573263 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
相似海外基金
Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
- 批准号:
23H02361 - 财政年份:2023
- 资助金额:
$ 21.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : GNT1124162 - 财政年份:2017
- 资助金额:
$ 21.19万 - 项目类别:
Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : 1124162 - 财政年份:2017
- 资助金额:
$ 21.19万 - 项目类别:
Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9300976 - 财政年份:2015
- 资助金额:
$ 21.19万 - 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9920805 - 财政年份:2015
- 资助金额:
$ 21.19万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8900121 - 财政年份:2012
- 资助金额:
$ 21.19万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8225814 - 财政年份:2012
- 资助金额:
$ 21.19万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8699511 - 财政年份:2012
- 资助金额:
$ 21.19万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8525355 - 财政年份:2012
- 资助金额:
$ 21.19万 - 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
- 批准号:
9115537 - 财政年份:1991
- 资助金额:
$ 21.19万 - 项目类别:
Standard Grant